liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Biological treatment of ankylosing spondylitis: a nationwide study of treatment trajectories on a patient level in clinical practice
Karolinska Inst, Sweden.
Lund Univ, Sweden.
Karolinska Inst, Sweden.
Region Östergötland, Heart and Medicine Center, Department of Rheumatology.
Show others and affiliations
2019 (English)In: Arthritis Research & Therapy, ISSN 1478-6354, E-ISSN 1478-6362, Vol. 21, article id 128Article in journal (Refereed) Published
Abstract [en]

BackgroundThere is substantial evidence that patients with ankylosing spondylitis (AS) have high response rates to tumour necrosis factor inhibitors (TNFi), a low likelihood of successful treatment termination, but yet a limited drug retention. Whereas several reports have assessed drug retention rates for TNFi in AS, there are few, if any, studies investigating the actual treatment trajectories on a patient level, including subsequent therapy changes and dose reductions, of individual patients. The aim of this study was to describe 5-year treatment trajectories in patients with ankylosing spondylitis (AS) starting a first TNFi.MethodsBio-naive patients with AS starting a TNFi in 2006-2015 were identified in the nationwide Swedish Rheumatology Quality register and followed until 31 December 2015. All changes in their anti-rheumatic treatment during follow-up were recorded. To further increase precision, these data were complimented by information on the amount of prescribed subcutaneous TNFi collected from pharmacies during each year, retrieved from the Swedish Prescribed Drug Register.ResultsTwo thousand five hundred ninety patients started a first TNFi 2006-2015, and after 1year, 74% remained on their first TNFi. However, after 5years, this figure was only 46%, although at that time 63% were still on treatment with any biologic, while 30% had no anti-rheumatic treatment at all. After discontinuing the first TNFi, 46% switched directly to a second TNFi, but the drug retention for the second and third TNFi grew successively shorter compared to that for the first TNFi. In contrast, patients remaining on treatment with their first subcutaneous TNFi gradually reduced the dose, so that during the fifth year of treatment only 66% had collected 75% of the defined daily doses for that year.ConclusionLess than half of patients with AS will remain on their first TNFi after 5years, but most are still on a biologic. While patients remaining on treatment with their first TNFi appear to be able to reduce the dose over time, a large proportion cycle through several biologics, and 1/3 have no anti-rheumatic treatment after 5years. This indicates the importance of thorough follow-up programs as well as a need for alternative therapeutic options.

Place, publisher, year, edition, pages
BMC , 2019. Vol. 21, article id 128
Keywords [en]
Ankylosing spondylitis; Tumour necrosis factor inhibitor; Treatment; Observational
National Category
Rheumatology and Autoimmunity
Identifiers
URN: urn:nbn:se:liu:diva-158328DOI: 10.1186/s13075-019-1908-9ISI: 000469446800001PubMedID: 31138285OAI: oai:DiVA.org:liu-158328DiVA, id: diva2:1333867
Note

Funding Agencies|Karolinska Institutet [NA]

Available from: 2019-07-02 Created: 2019-07-02 Last updated: 2019-07-02

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Qirjazo, Ilia
By organisation
Department of Rheumatology
In the same journal
Arthritis Research & Therapy
Rheumatology and Autoimmunity

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 1 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf